About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Alnylam Pharma Reveals Data Showing RNAi Therapeutic Can Silence Angiopoietin 2 - Quick Facts

Monday, November 06, 2006; Posted: 10:26 AM

Find out where ALNY is going
Use our most popular trading tool to find
out how ALNY will move in the next
5 days.




Stocks rated 9 and 10 have outperformed the average stock by approximately 14 to 1 since 1995 and ideally are the stocks to focus on each day. Stocks rated 1 and 2 on average have lost money and you want to know these stocks in order to avoid them.

Click here for more details



(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY | charts | news | PowerRating) on Monday revealed the publication of data demonstrating that an RNAi therapeutic can silence angiopoietin 2, a key mediator in acute lung injury. The study published in Nature Medicine prepared by scientists from Yale University and Alnylam demonstrated inhibition of acute lung injury and cell death in animals with administration of small interfering RNAs, the molecules that mediate RNAi, targeting Ang2. According to the company, the vivo data showed silencing of Ang2 in the lung, and contribute to existing data demonstrating the potential for developing RNAi therapeutics that target diseases associated with the lungs.

RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes.

Driver - I'm a bit confused, re the header:

Uni. of Aberdeen 4.0%
Also
University Of Aberdeen 5.8%

Are there two universities?

LOL

ones a plc and the other is limited ;-)

Thankyou PH.

EiRx Therapeutics plc
('the Company')


Ordinary Shares of 0.2p


The Company was notified on 3 November 2006 that Zyzygy plc no longer has a
notifiable interest in the Company.

They must have seen you put them in the header Driver!
kim

Well that puts things in a different perspective.

Why would they sell if they saw value from coming one off payments?

Why would they sell if they were aware, being in the same business, that ERX are on the crest of a whole new standing within the pharmaceutical world?

Answers, they wouldn't!

they probably needed the money for their new investment they announced yesterday. !!!! : )

LONDON (AFX) - Zyzygy PLC said it has increased its holding in software company Nice Tech to 45.9 pct from 41 pct.

In mid-July, Zyzygy had raised its stake in Cambridge-based Nice Tech to 41 pct from 32 pct.

newsdesk@afxnews.com

Zyzygy PLC
06 November 2006


Zyzygy plc

Investment in Nice Tech Limited ('Nice Tech')

The directors of Zyzygy plc today announce that they have increased their
holding in Nice Tech from 41 per cent. to 45.9 per cent.

Nice Tech is a Cambridge based software company that is developing unique
software (called AliceServerAR) that allows for complex, large scale simulated
environments to be built and accessed by thousands of participants via the
Internet.

Zyzygy plc is a company that invests in high technology companies where there
are perceived to be 'near to market opportunities'.



Contact:

http://phx.corporate-ir.net/phoenix.zhtml?c=70584&p=irol-eventdetails&EventId=1408582

Web cast about to start on OSI

;-)

the Oncology bit is ours;;;;;;; Z;-)

LONDON (AFX) - EiRx Therapeutics PLC, the healthcare company specialising in
the control of programmed life and death of cells (apoptosis), said OSI
Pharmaceuticals has opted to license four of its drug targets, thereby
triggering first milestone payment with a potential value of up to 18.8 mln usd.
In a statement, the company said OSI Pharmaceuticals has opted to license
and take forward four of its gene targets into drug discovery for oncology.
A success fee for each target is payable by OSI Pharmaceuticals, as part of
a deal consisting of upfront access and consultancy fees, potential success fees
for each target elected by OSI Pharmaceuticals to license and potential
milestone payments based on successful commercialisation of a novel therapeutic
with respect to each such target.
newsdesk@afxnews.com
ra/ak

so what you reckon, news tomorrow from ERX re Oncology

I'm away this week so will not be posting till next week up in bonny Scotland.

what. so you not going to be around when the news is announced then

Driver have fun in Scotland, and the sp will still probably be .30 when you get back !!! : )

of interest : )

Physiomics PLC
07 November 2006


Physiomics plc ('Physiomics' or the 'Company')


Ordinary Shares of 0.04p


The Company was today informed of the following shareholdings:


EiRx Pharma Limited:
134,834,208 shares representing 36.0 % of the Company's issued share capital


Zyzygy plc:
25,000,000 shares representing 6.7 % of the Company's issued share capital


Billam plc:
41,232,844 shares representing 11.0 % of the Company's issued share capital


Zyzygy plc acquired 25,000,000 shares and Billam plc acquired 33,333,333 shares
in the placing first announced on 1 September 2006.


This information is provided by RNS

Incestuous investments.

and whats wrong with that ;-)

Dont be touchy, did I say there was anything wrong with it?

up and no buys, just sells.. very odd

in case any of you are wondering why ZYZ are buying PYC shares, think about it, our director sits on ZYZ board, to take over PYC we will need a controlling share, ZYZ bought ERX shares in 2005 for .0030 and are now selling ERX at .0030, reason.. M&A taking place.

I also think the reason why this is happening is ERX know how much money is coming from OSI and MGI and its far more than we were estimating.

rerating - M&A def on the cards